Journal Article Review Epublish 1 citation
PubMed: 40756669 DOI: 10.1093/noajnl/vdaf135
Advancing vaccine-based immunotherapy in glioblastoma treatment.
Neurooncol Adv 7(1):vdaf135
Authors: Desh Deepak Singh, Shafiul Haque, Abhishek Kumar Singh, Dharmendra Kumar Yadav
Affiliations
- Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India.
- Department of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia and School of Medicine, Universidad Espiritu Santo, Samborondon, Ecuador.
- Manipal Centre for Biotherapeutics Research (MCBR), Manipal Centre for Biotherapeutics Research, Manipal Academy of Higher Education, Manipal, India.
- Department of Biologics, College of Pharmacy, Gachon University, Yeonsu-gu, Incheon, Republic of Korea.
Abstract
Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials. This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.
MeSH
Cells, Vaccines, Neoplasms, Immunotherapy, Glioblastoma, Therapeutics, Vaccine Efficacy